High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Over the last 7 days, the United States market has dropped 2.4%, yet it remains up by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying undervalued stocks can be particularly appealing as they may offer significant potential for appreciation when their intrinsic value is recognized by the market.
Over the last 7 days, the United States market has dropped 2.4%, though it has risen by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying stocks that might be trading below their estimated intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.
If you own JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), you bought it for a reason that still holds. JEPI pays monthly. It leans on a defensive equity sleeve and runs a covered call overlay that turns volatility into income. It is the largest active ETF in the country, yielding near 8.2%. But a younger competitor now runs the same ... Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch
AbbVie (NYSE:ABBV) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet carrying negative shareholders’ equity of -$6.6 billion complicates conviction at this price. AbbVie is the immunology heavyweight behind Skyrizi, Rinvoq, and legacy Humira, ... Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $225.42 as of June 9th. ABBV’s trailing and forward P/E were 110.50 and 15.82 respectively according to Yahoo Finance. AbbVie […]
Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Over the last 7 days, the United States market has experienced a 4.1% drop, although it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In such fluctuating conditions, identifying stocks that might be undervalued based on current market estimates can present opportunities for investors seeking potential growth at a reasonable price.
Mid-year is when income-focused investors tend to take a hard look at their portfolios. With the second half of 2026 ahead, retirees and near-retirees are leaning into reliable dividend payers that can keep checks coming through any summer volatility. The three names below combine long dividend histories, defensive cash flows, and recent raises, exactly the ... 3 Dividend Stocks Built for Retirement to Buy in June
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up 22% over the past year with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying stocks that are potentially priced below their intrinsic value can offer opportunities for investors seeking long-term growth, such as Coastal Financial and two other noteworthy companies.
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up by 22% over the past year, with earnings expected to grow by 17% annually in the coming years. In this fluctuating environment, identifying stocks that may be trading at a discount can offer investors opportunities to capitalize on potential value gains.
Over the last 7 days, the United States market has experienced a 2.7% drop, though it has risen by 23% over the past year, with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying undervalued stocks can present opportunities for investors seeking to capitalize on potential growth and favorable market estimates.
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
Over the last 7 days, the United States market has experienced a 2.7% decline, yet it remains up by 23% over the past year with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be below their fair value can present opportunities for investors looking to capitalize on potential growth amid current market fluctuations.
Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
A retiree’s $40,000 dividend income stream sounds modest next to a neighbor’s $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The ... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
